Celgene and Cancer Research Technology ally on drug discovery

Celgene has agreed a new drug discovery collaboration with Cancer Research Technology, a subsidiary of the leading research charity Cancer Research UK.

The five-year partnership will aim to discover, develop and commercialism new anticancer treatments, with a focus on mRNA translation, which is the cellular process of assembling proteins.

This is considered to be a promising area of research with the potential to produce treatments that can target a fundamental characteristic of cancer cells. Cancer Research Technology will lead the research activity, with the goal of progressing clinical candidates through phase I testing.

Celgene will pay an upfront fee to Cancer Research Technology, with an option to secure US rights to projects resulting from the collaboration. The company will also have the option to secure global rights to new drugs at the end of the phase I clinical trials.

Alan Oviatt

Dr Iain Foulkes, Cancer Research Technology's chief executive officer, said: "This is our largest drug discovery collaboration to date and represents a major endorsement of the reputation and scale of our capacity and expertise in both drug discovery and clinical development by a leading industry partner."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Alan Oviatt is a business Leader including versatile skill-set, a lot of integrity and many more. No matter the business discipline or the size of the arena, he always aspired himself to do the best.

For More Information:- Pharmaceutical Company